|
|
Vaccine Detail
|
Brucella abortus salt-extractable protein vaccine |
| Vaccine Information |
- Vaccine Name: Brucella abortus salt-extractable protein vaccine
- Target Pathogen: Brucella spp.
- Target Disease: Brucellosis
- Vaccine Ontology ID: VO_0009046
- Type: Subunit vaccine
- Status: Research
- Host Species for Licensed Use: Cattle
- Host Species as Laboratory Animal Model: Mus musculus (BALB/c mice); Dicrostonyx rubricatus (lemmings); lemmings; guinea pigs; rabbits; Cattle
- Antigen: salt-extractable protein | salt-extractable proteins including proteins of molecular weights 30,000; 20,000; and 12,000 | salt-extractable proteins | soluble salt-extractable protein antigens (CSP) from Brucella abortus; chemically modified proteins with dodecanoyl anhydride
-
Adjuvant:
mophosphoryl lipid A; trehalose dimycolate
- Preparation: Salt-extractable protein given alone or combined with MPL or TDM adjuvants. (Tabatabai et al, 1992)
Vaccines contained salt-extractable proteins (CSP); chemically modified dodecanoyl-CSP vaccines were also tested but showed no additional advantage. (Tabatabai et al, 1989)
Soluble protein preparations, including chemically modified proteins with dodecanoyl anhydride to enhance immunogenicity. (Tabatabai et al, 1984)
- Description: The study evaluated the effect of monophosphoryl lipid A (MPL) and trehalose dimycolate (TDM) as adjuvants on the protective responses of the salt-extractable protein vaccine in BALB/c mice. Efficacy: Vaccination with salt-extractable protein reduced spleen weights and Brucella CFU compared to controls; MPL enhanced suppression of splenic infection when combined with salt-extractable protein; TDM had no effect on CFU with salt-extractable protein. Immune response: Serum IgG and IgM specific for vaccine antigens were measured; no conclusive alteration in spleen cell interleukin-1 production was observed due to wide variation. (Tabatabai et al, 1992)
The vaccine was introduced as salt-extractable proteins from Brucella abortus, evaluated for immunogenicity. Efficacy: Vaccination with as little as 0.1 microgram of CSP suppressed splenic infection, reducing viable Brucella by 5-6 logs compared to controls; protein fractions were generally effective in reducing splenic infection. (Tabatabai et al, 1989)
Vaccination of crossbred beef heifers with Brucella abortus salt-extractable proteins was performed to induce specific immunoglobulin isotype responses. Efficacy: Vaccinated heifers had higher antibody responses than baseline for at least 31 weeks post-vaccination; however, after challenge exposure, no significant differences in antibody responses were detected between vaccinated and nonvaccinated heifers; vaginal antibody responses did not correlate with protection; serotests could distinguish baseline titers from those of heifers that aborted and were culture-positive but could not consistently distinguish vaccinates from challenge-exposed cattle or differentiate aborted from non-aborted challenge-exposed heifers. Immune response: Vaccination induced Brucella-specific IgG and other immunoglobulin isotypes in serum and vaginal mucus; vaginal IgM was detected only at abortion; vaginal IgA was specific for virulent infection and was effective in distinguishing vaccinated from challenge-exposed heifers and aborted from non-aborted heifers; serum IgA was detected up to 13 weeks after abortion. (Hall et al, 1989)
Soluble salt-extractable protein antigens from Brucella abortus, mainly from the periplasmic space and nonporin outer membrane proteins, were isolated using mild extraction methods. Efficacy: Immunization with dodecanoyl-modified proteins decreased humoral antibody levels without loss of protective activity in lemmings. Immune response: Protein preparations were antigenic in guinea pigs, rabbits, and cattle, and immunogenic in lemmings, guinea pigs, and cattle; chemical modification enhanced immunogenicity while reducing humoral antibody levels. (Tabatabai et al, 1984)
|
| Host Response |
|
|
| References |
Hall et al, 1989: Hall SM, Confer AW. Brucella abortus-specific immunoglobulin isotypes in serum and vaginal mucus from heifers vaccinated with Brucella abortus salt-extractable proteins and challenge exposed with virulent Brucella organisms. American journal of veterinary research. 1989 Dec; 50(12); 1997-2003. [PubMed: 2514615].
Tabatabai et al, 1984: Tabatabai LB, Deyoe BL. Biochemical and biological properties of soluble protein preparations from Brucella abortus. Developments in biological standardization. 1984; 56; 199-211. [PubMed: 6436094].
Tabatabai et al, 1989: Tabatabai LB, Deyoe BL, Patterson JM. Immunogenicity of Brucella abortus salt-extractable proteins. Veterinary microbiology. 1989 May; 20(1); 49-58. [PubMed: 2503922].
Tabatabai et al, 1992: Tabatabai LB, Pugh GW, Stevens MG, Phillips M, McDonald TJ. Monophosphoryl lipid A-induced immune enhancement of Brucella abortus salt-extractable protein and lipopolysaccharide vaccines in BALB/c mice. American journal of veterinary research. 1992 Oct; 53(10); 1900-7. [PubMed: 1456539].
|
|
